Improvement of mouse beta-thalassemia by recombinant human erythropoietin

Improvement of Mouse &Thalassemia by Recombinant Human Erythropoietin

Homozygous 8 thalassemic mice received 50 U (1,660 U/kg) of recombinant human erythropoietin (rhEpo) 5 days a week for 2 weeks. Hemoglobin increased from 9.2 2 0.6 g/dL to 10.5 f 0.4 g/dL (P = .002) and hematocrit increased from 29.2% f 0.9% to 34.1% f 1.9% (P = .0014). The p minor/a globin chain synthesis ratio increased slightly but significantly between day -4 (0.75 f 0.07) and day 4 (0.81 f...

Improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG–PLA micelle

To improve the pharmacokinetics and stability of recombinant human erythropoietin (rhEPO), rhEPO was successfully formulated into poly(ethylene glycol)-poly(d,l-lactide) (PEG-PLA) di-block copolymeric micelles at diameters ranging from 60 to 200 nm with narrow polydispersity indices (PDIs; PDI < 0.3) and trace amount of protein aggregation. The zeta potential of the spherical micelles was in th...

Hyporesponsiveness to recombinant human erythropoietin.

The introduction of recombinant human erythropoietin (rh-Epo, epoetin) as a treatment for the anaemia of renal failure has transformed the management of this condition. Nevertheless, a significant number of patients fail to respond. There are many different possible causes of inadequate response to epoetin. Iron deficiency, whether absolute or functional, is considered to be the most important,...

Testing for recombinant human erythropoietin.

ERYTHROPOIETIN (Epo) may have effects on exercise capacity and physiological regulation beyond a simple increase in red cell mass and the associated improvement in oxygen transport (4). In the context of a larger study on this topic, Lundby and colleagues (11) also asked questions about the reliability of urine testing for recombinant human Epo (rHuEpo). They studied eight healthy male subjects...

Beta-Thalassemia Carrier Detection by NESTROFT